3SBio Inc. (HKG:1530)
Hong Kong · Delayed Price · Currency is HKD 19.99
-0.17 (-0.84%)
May 15, 2026, 4:09 PM HKT
3SBio Revenue
In the year 2025, 3SBio had annual revenue of 17.70B CNY with 94.29% growth. 3SBio had revenue of 13.34B in the half year ending December 31, 2025, with 230.85% growth.
Revenue
17.70B CNY
Revenue Growth
+94.29%
P/S Ratio
2.54
Revenue / Employee
2.90M CNY
Employees
6,109
Market Cap
49.99B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17.70B | 8.59B | 94.29% |
| Dec 31, 2024 | 9.11B | 1.29B | 16.53% |
| Dec 31, 2023 | 7.82B | 950.20M | 13.84% |
| Dec 31, 2022 | 6.87B | 483.73M | 7.58% |
| Dec 31, 2021 | 6.38B | 794.37M | 14.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sino Biopharmaceutical | 35.43B |
| Genscript Biotech | 7.47B |
| Shanghai Henlius Biotech | 7.42B |
| RemeGen | 3.84B |
| Akeso | 3.40B |
| Shanghai Junshi Biosciences | 3.10B |
| InnoCare Pharma | 2.87B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.29B |
3SBio News
- 1 year ago - Pfizer Signs $6B Deal with 3SBio for China-Based Cancer Drug - TipRanks